Press Release

Zetagen Therapeutics, Inc. Receives Patent for Regulation of Bone Growth and Bone Degradation Using Small-Molecule

23 April 2019

U.S.-based biopharmaceutical company has discovered and patented a novel molecular pathway intended to treat metastatic bone lesions
Latest patent issuance follows previous patents for methods in stimulating bone growth using ZetaMet™ (Zeta-BC-003)
New patent further enhances the Company’s Global IP strategy

April 23, 2019 – (Syracuse, New York) - Zetagen Therapeutics, Inc., a private, US-based biotechnology company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions, announced today that the U.S. Patent and Trademark Office (“USPTO”) issued U.S. Patent No. 102656437 to the Company. This patent, entitled Neurogenic Regulation of Bone Growth and Bone Degradation, covers the use of methods for promoting controlled bone creation and destruction as a means to repair large bone segmental defects. This patent follows the previously issued U.S. Patent No. 10208306 and South African PCT. 2017/00029 covering the use of a method for stimulating bone growth using a small molecule.

“This latest patent issuance is a significant piece of our Global IP Strategy. This provides the opportunity to further develop our therapies to aid patients afflicted by metastatic lesions,” said Joe C. Loy, CEO of Zetagen Therapeutics, Inc.

The new patent is part of an expanding and comprehensive portfolio of patents, patent applications and other intellectual property covering the composition, synthesis, manufacturing, formulations and uses for the treatment of a variety of metastatic bone lesions and osteologic interventions. Zetagen exclusively licensed its platform technology from the State University of New York in 2016.

About Zetagen Therapeutics

Zetagen has three novel drugs in development with the Zeta Platform, ZetaMet™ (Zeta-BC-003), for the treatment of metastatic breast cancer to bone, ZetaMast™ (Zeta-MBC-005) for breast cancer liver metastases (BCLM), and ZetaPrime™ (Zeta-PBC-007) for the treatment of primary HR+ breast cancer, all with inspiring results. To learn more, visit www.zetagen.com. The entire Zeta platform is designed for intratumoral administration to reduce off-target toxicity, utilizing proprietary carriers—some incorporating our New Molecular Entity. The USPTO has granted Zetagen Composition-of-Matter patents and claims for all three therapeutics.

Zetagen Upcoming Events

Zetagen will attend the 2025 San Antonio Breast Cancer Symposium (SABCS) and the 2026 JP Morgan Healthcare Conference.

Forward-Looking Statements

This press release contains certain forward-looking statements with the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. Source: Zetagen Therapeutics, Inc.